Post-earnings recap
Reported
Wed, May 6, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share that was slightly worse than expected, but the stock saw a modest increase of 0.42%. This reaction may reflect investor confidence in the company's ongoing clinical trials and future potential, despite the lack of revenue figures and guidance. Overall, the market seems to be taking a wait-and-see approach.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.73 | N/A | -4.29% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the current market conditions. They emphasized their commitment to advancing their clinical programs despite the lack of specific guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and developments.